Every few autumns, a virus most people have never heard of resurfaces in the medical press with an unsettling headline attached to it. Enterovirus D68 — EV-D68 for short — is that virus this fall. It broke into public awareness in 2014, when a nationwide wave of childhood respiratory illness coincided with a spike in a rare, polio-like paralysis called acute flaccid myelitis. New genomic surveillance published over the past year shows EV-D68 is not only still circulating but actively recombining into new lineages, and 2026 arrives as the kind of year clinicians have learned to watch. The goal of this piece is not to alarm anyone. It is to separate what the evidence supports from what the headlines imply, and to be honest about the one modest, practical thing that sits inside a clinic's control: the surfaces and the hands between patients.

What EV-D68 actually is

Enterovirus D68 is one of more than one hundred non-polio enteroviruses. Most of the time it behaves like a common cold. The CDC describes the usual picture as runny nose, sneezing, cough, and body aches, with more serious cases progressing to wheezing and difficulty breathing. Children — especially those with a history of asthma or reactive airways — are the group most likely to end up in an urgent care or an emergency department with it, because they have the least prior immunity and the most sensitive airways.

The virus spreads the way most respiratory viruses do: through secretions from the nose and mouth when someone coughs or sneezes, and through surfaces that those secretions land on and that another person then touches. It peaks in summer and fall and tapers through the winter, though it circulates at low levels year-round. There is no vaccine and no specific antiviral; care is supportive, and prevention rests on the unglamorous basics of hand hygiene, respiratory etiquette, and cleaning the things people share.

By the numbers

The paralysis question, answered carefully

The reason EV-D68 carries weight far beyond an ordinary cold virus is its association with acute flaccid myelitis, or AFM — a sudden weakness or paralysis in one or more limbs that most often strikes young children, typically a week or two after a respiratory or febrile illness. It is rare, but it is serious: in CDC surveillance from 2020 through 2025, nearly every confirmed patient was hospitalized, roughly half to three-quarters needed intensive care, and a meaningful share required a ventilator.

Here is the part the headlines usually leave out. AFM in the United States has followed a striking every-other-year rhythm, with sharp increases in 2014, 2016, and 2018 — the CDC counted 120, 153, and 238 confirmed cases in those three peak years, with most cases arriving between August and November. And then the pattern changed. Since 2018, confirmed AFM has stayed flat at baseline: between 17 and 48 cases a year, with 25 in 2024 and 17 in 2025.

In other words, the virus coming back does not automatically mean the paralysis comes back with it. The CDC's 2026 Morbidity and Mortality Weekly Report on AFM surveillance put it plainly: AFM cases have remained at baseline levels since 2018, even as EV-D68 circulated, and continued surveillance is needed to understand why. That uncertainty is the honest headline — not a prediction of catastrophe, and not an all-clear either.

Why 2025 got virologists' attention

If AFM has stayed quiet, why is EV-D68 in the literature at all this year? Because the virus itself is doing something interesting. A genomic surveillance study tracking EV-D68 through 2025 reported that of 1,321 patients tested at a Maryland health system between May and December, 147 — about 11 percent — were positive for the virus, with test positivity peaking near 21 percent in August and staying elevated into October. More notably, the researchers identified a new recombinant lineage: a strain that had swapped genetic material between two previously distinct EV-D68 clades.

Recombination is how enteroviruses shuffle their decks. A new combination can, in principle, change how easily a virus spreads or how the immune system recognizes it — though whether this particular lineage does either is still unknown. The practical takeaway for a clinic is not the genetics; it is the reminder that EV-D68 is an active, moving target, that it surged outside its old biennial script in 2025, and that fall is its season. For a pediatric practice, an urgent care, or any clinic that sees children, that is reason enough to make sure the ordinary defenses are actually in place.

Why this is a surfaces-and-hands story

Here is where EV-D68 connects to something a clinic can act on today, and it comes down to one piece of virology. Enteroviruses are non-enveloped viruses: they lack the fragile outer lipid coat that surrounds influenza, RSV, and the coronaviruses. That coat is exactly what alcohol-based hand sanitizers are good at dissolving. Strip it away, and the virus falls apart. Non-enveloped viruses have no such coat, so they are considerably harder to inactivate — which is why the same gap that makes alcohol gel unreliable against norovirus applies to enteroviruses too.

This is not a fringe claim. It is the reason the CDC tells the public that hand sanitizer is not a substitute for washing with soap and water against norovirus, the best-known non-enveloped virus. The same logic governs surfaces. A product that carries an EPA-registered kill claim against a tough non-enveloped target has been tested against the hard case — not just the easy, enveloped ones. For respiratory and enterovirus season in a room full of children, that distinction is the whole game.

For the high-touch surfaces children share

SONO Disinfecting Wipes — 80ct Canister

EPA-registered (Reg. #6836-340-89018), alcohol-free, and bleach-free. Kill claims include norovirus, influenza A, RSV, and SARS-CoV-2. Made in the USA.

Shop SONO Wipes

A between-patient surface routine for a busy fall clinic

None of this needs a new budget line or a new committee. It needs a short, written routine that a front-desk hire or a float nurse can follow on the busiest Saturday of October. Treat the sequence below as a starting point to adapt to your own equipment manufacturers' instructions for use and your medical director's policies.

What makes this season different is not the routine — it is the traffic. Fall layers EV-D68 on top of the viruses a clinic already expects. The CDC's 2026–2027 respiratory season outlook projects a combined flu, COVID-19, and RSV burden broadly similar to last winter, with a moderate flu season across all ages. More sick children in the waiting room means more secretions on more surfaces, and the between-patient routine is the thing that keeps that from compounding.

EV-D68 may stay quiet this fall, as AFM has since 2018, or the new lineage may give the season a different shape. A clinic cannot control which of those happens. It can control whether the exam table was disinfected for the full contact time, whether staff reached for soap over gel, and whether the wipes on the shelf were chosen for the hard case rather than the easy one. That is a small amount of certainty in an uncertain season — and it is worth having in place before the surge that may or may not come.

For backpacks, diaper bags, and the front desk.

SONO Travel-Size Disinfecting Wipes keep the same EPA-registered, alcohol-free formula in a grab-and-go pack for school, car, and clinic.

See Travel Wipes

Related reading

• Norovirus 2026–2027: Why the New GII.17 Strain Shrugs Off Hand Sanitizer — and What Actually Kills It on Surfaces
• Back to School, Back to Germs: The 4 Viruses Surging Right Now and What Actually Kills Them on Surfaces
• Flu Season 2026–2027 Arrives With a Drifted Strain: What Subclade K Means for the Clinic — and the Surfaces In It